Inhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo

Angiogenesis

Volumn 18, Issue 1, 2015, Pages 31-46

  Contois, Liangru W ^a   Akalu, Abebe ^a   Caron, Jennifer M ^a   Tweedie, Eric ^a   Cretu, Alexandra ^b   Henderson, Terry ^a   Liaw, Lucy ^a   Friesel, Robert ^a   Vary, Calvin ^a   Brooks, Peter C ^a  

^a Maine Medical Center Research Institute   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; IGFBP 4; Insulin like growth factor; Integrin; Melanoma; MMPs; p38 MAPK

Indexed keywords

MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SOMATOMEDIN BINDING PROTEIN 4; VITRONECTIN RECEPTOR; PRIMER DNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COMPLICATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; NEOVASCULARIZATION, PATHOLOGIC; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INTEGRIN ALPHAVBETA3; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; X-RAY MICROTOMOGRAPHY;

EID: 84922070880     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9445-2     Document Type: Article

References (62)

1. Varney ML, Jonansson SL, Singh RK (2005) Tumor-associated infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 15:417–425
2. Demirkesen C, Buyukpinarbasili N, Ramazangoglu R, Ollguz O, Mandel NM et al (2006) The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblast growth factor. Pathology 38:132–137
3. Massi D, Franchi A, Borgognoni L, Paglierani M, Reali UM et al (2002) Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphological analysis. Virchow Arch 440:22–28
4. Wu S, Singh S, Varney ML, Kindle S, Singh RK (2012) Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. Cancer Med 3:306–317
5. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D et al (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325
6. Contois L, Akalu A, Brooks PC (2009) Integrins as functional hubs in the regulation of pathological angiogenesis. Semin Cancer Biol 19:318–328
7. Indraccolo S (2013) Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. Adv Exp Med Biol 734:37–52
8. Kang SY, Watnick RS (2008) Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF. APMIS 116:638–647
9. Almog N, Ma L, Rachowdhury R, Schwager C, Erber R et al (2009) Transcriptional switch of dormant tumors to fast growing angiogenic phenotype. Cancer Res 69:836–944
10. Moserle L, Amadori A, Indraccolo S (2009) The angiogenic switch: implications in the regulation of tumor dormancy. Curr Mol Med 8:935–941
11. Chung AS, Lee J, Ferrara N (2010) Targeting the tumor vasculature: insight from physiological angiogenesis. Nat Rev Cancer 10:505–513
12. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307
13. Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–1369
14. Ebos JM, Lee CR, Kerbel RS (2009) Tumor and host-mediated pathways of resistance and disease progression in response to anti-angiogenic therapy. Clin Cancer Res 16:5020–5025
15. Ebos JM, Lee CR, Cruz-Munzo W, Bjarmason GA, Christensen JG et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232–239
16. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increase local invasion and distant metastasis. Cancer Cell 15:220–231
17. Hangai M, Kitaya N, Chan CK, Kim JJ, Werb Z et al (2002) Matrix metaaloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 161:1429–1437
18. Chen Q, Jin M, Yang F, Zhu J, Xiao Q et al (2013) Matrix metalloproteinases: inflammatory regulators of cell behavior in vascular formation and remodeling. Mediators Inflamm. doi:10.1155/2013/928315
19. Xu X, Rodriguez D, Petitclerc E, Kim JJ, Hangai M et al (2001) Proteolytic exposure of a cryptic site within collagen type-IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069–1079
20. Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196:395–406
21. Assal Y, Mie M, Kobatake E (2013) The promotion of angiogenesis by growth factors integrated with ECM proteins through coiled-coil structures. Biomaterials 34:3315–3323
22. Davis GE (2011) Angiogenesis and proteinase: influence on vascular morphogenesis, stabilization and regression. Drug Discov Today Dis Models 8:13–20
23. Sweet DT, Chen Z, Wiley DM, Bautch VL, Tzima E (2012) The adaptor protein Shc integrates growth factor and ECM signaling during postnatal angiogenesis. Blood 119:1946–1955
24. Sacharidou A, Stratman AN, Davis GE (2012) Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices. Cells Tissues Organs 195:122–143
25. Petitclerc E, Boutaud A, Prestrayko A, Xu J, Sado Y et al (2000) New functions for non-collagenous domains of human collagen type-IV: novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275:8051–8061
26. Ren B, Yee KO, Lawer J, Khosrav-Far J (2006) Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 1765:178–188
27. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22
28. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264:569–571
29. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T et al (1994) Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164
30. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K et al (2008) Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors. Investig New Drug 26:35–43
31. Scaringi C, Minniti G, Caporello P, Enrici RM (2012) Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 32:4213–4223
32. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD et al (2002) Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med 8:27–34
33. Taverna D, Moher H, Crowley D, Borsig L, Varki A et al (2004) Increased primary tumor growth in mice null for β3 or β3 and β5 integrins or selectins. Proc Natl Acad Sci USA 101:763–768
34. Feng W, McCabe P, Mahabeleshwar GH, Samanath PR, Phillips DR et al (2008) The angiogenic response is dictated by β3 integrin on bone marrow-derived cells. J Cell Biol 182:1145–1157
35. Cretu A, Roth JM, Caunt M, Akalu A, Policarpio D et al (2007) Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin Cancer Res 13:3068–3078
36. Akalu A, Roth JM, Caunt M, Policarpio D, Liebes L et al (2007) Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin. Cancer Res 67:4353–4363
37. Contois LW, Nugent DP, Caron JM, Cretu A, Tweedie E et al (2012) Insulin-like growth factor binding protein-4 differentially inhibits growth factor-induced angiogenesis. J Biol Chem 287:179–189
38. Smith LEH, Shen W, Perruzzi C, Soker S, Kinose F et al (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 12:1390–1395
39. Moreno MJ, Ball M, Andrade MF, Mcdermid A, Stanimirovic DB (2006) Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia 63:845–857
40. Beattie J, McIntosh L, Walle V (2010) Cross talk between the insulin-like growth factor (IGF) axis and membrane integrins to regulate cell physiology. J Cell Physiol 224:605–611
41. Rossello A, Orlandini E, Carelli P, Rapposelli S, Macchia M et al (2004) New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP2). Bioorg Med Chem 12:2441–2450
42. Freimark B, Clark D, Pernasetti F, Nickel J, Myszka D et al (2007) Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagens. Mol Immunol 44:3741–3750
43. Mondy WL, Cameron D, Timmermans JP, De Clerck N, Sasov AC et al (2009) Micro-CT or corrosion casts for use in the computer-aided design of microvasculature. Tissue Eng Part C Methods 15:729–738
44. Felding-Habermann B, Mueller BM, Romerdahi CA, Cheresh DA (1992) Involvement of integrin alpha v expression in human melanoma tumorigenicity. J Clin Investig 89:2018–2022
45. Durai R, Davis M, Yang W, Yang SY, Seifalian A et al (2006) Biology of insulin-like growth factor binding protein-4 and its role in cancer. Int J Oncol 28:1317–1325
46. Yu JZ, Warycha MA, Christos PJ, Darvishian F, Yee H et al (2008) Assessing the clinical utility of measuring insulin-like growth factor binding proteins in tissues and sera from melanoma patients. J Transl Med 6:70. doi:10.1186/1479-5876-6-70
47. Estrada Y, Dong J, Ossowski L (2009) Positive crosstalk between Erk and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res 22:66–76
48. Hennig T, Mogensen C, Kirsch J, Pohl U, Gloe T et al (2011) Shear stress induces the release of an endothelial elastase: role in integrin αvβ3-mediated FGF-2 release. Vasc Res 48:453–464
49. Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T et al (2005) Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 333:1011–11016
50. Prudova A, auf dem Keller U, Butler GS, Overall CM (2010) Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics. doi:10.1074/mcp.M000050-MCP201
51. Denkert C, Siegert A, Leclere A, Turznski A, Hauptmann S (2002) An inhibitor of stress-activated MAP-kinase reduces invasion and MMP-2 expression of malignant melanoma cells. Clin Exp Metastasis 19:79–85
52. Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC (2012) TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer. doi:10.1186/1471-2407-12-26
53. Reynolds AR, Reynolds LE, Nagel TE, Robinson SD, Hicklin DJ et al (2004) Elevated FLK1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Res 64:8643–8650
54. Waston RA, Pitchford SC, Reynolds LE, Direkze N, Alison MR et al (2010) Deficiency of bone marrow β3-integrin enhances non-functional neovascularization. Am J Pathol 220:435–445
55. Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Scheider JG et al (2014) Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice. Circ Res 114:79–91
56. Robinson SD, Hodivala-Dilke KM (2011) The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 23:630–670
57. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA et al (1996) Definition of two angiogenic pathways by distinct αv integrins. Science 270:1500–1502
58. Lorger M, Krueger JS, O’Neal M, Staflin K, Felding-Habermann B (2009) Activation of tumor cell integrin αvβ3 controls angiogenic and metastatic growth in the brain. Proc Natl Acad Sci USA 106:10666–10671
59. Gloe T, Sohn HY, Meininger GA, Pohl U (2002) Shear stress-induced release of basic fibroblast growth factor from endothelial cells is mediated by matrix interaction via integrin αvβ3. J Biol Chem 277:23453–23458
60. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA (1996) Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Investig 98:426–433
61. Bao W, Stomblad S (2004) Integrin αv-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol 167:745–756
62. Teodora JG, Parker AE, Zhu X, Green MR (2006) P53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313:968–997